

Thursday, 09. February 2023

Physicians Session
13:00 - 13:15

Plenary

OP - Opening Ceremony

Chair: Michael Hudecek, DE

Chair: Anna Sureda, ES

Physicians Session
13:15 - 14:45

Plenary

PS01 - Clinical Indications I - Lymphomas

Chair: Catherine Thieblemont, FR

Chair: Marie José Kersten, NL

PS01-1	Large B Cell Lymphoma (LBCL) <i>Speaker:</i> Anna Sureda, ES	13:15 - 13:35
PS01-2	Mantle Cell Lymphoma (MCL) / Follicular Lymphoma (FL) <i>Speaker:</i> Ulrich Jaeger, AT	13:35 - 13:55
PS01-3	Resistance <i>Speaker:</i> Marco Ruella, US	13:55 - 14:20
PS01-4	The role of the intestinal microbiome in cancer immunotherapy <i>Speaker:</i> Marcel Van den Brink, US	14:20 - 14:45

Poster Session
13:15 - 20:00

Poster Area

Poster Posters are at the exhibition area during the 3 days of the meeting and available on the virtual event platform. There is not any scheduled presentation.

Mathematical Optimization of Personalized CAR-T Cell Products <i>Poster Presenter:</i> John J. L. Jacobs, NL	13:15 - 13:15
Nurse-led Long Term Follow up Clinic <i>Poster Presenter:</i> Olivia Lamb, GB	13:15 - 13:15
Cooccurrence of CRS and ICANS in Anti-CD19 CAR T-cell Treatments <i>Poster Presenter:</i> Vibhu Agarwal, US	13:15 - 13:15
Molecular Mechanisms of CAR-T Cell Response in MM <i>Poster Presenter:</i> Juan R. Rodriguez-Madoz, ES	13:15 - 13:15
Three-year Follow-up of ZUMA-3: Brexucabtagene Autoleucel in R/R B-ALL <i>Poster Presenter:</i> Tsveta Hadjivassileva, GB	13:15 - 13:15
Real-time Prediction of CAR-T Cell Concentrations and Optimal Harvest Times <i>Poster Presenter:</i> Stephen Goldrick, GB	13:15 - 13:15
<i>In vivo</i> Tumor Microscopy in a Medulloblastoma Mouse Model <i>Poster Presenter:</i> Julika J. Herold, DE	13:15 - 13:15

Anti-tumor Response of TCR-engineered iNKT Cells	13:15 - 13:15
<i>Poster Presenter:</i> Gloria Delfanti, IT	
Expanding Access to CART Therapy via Local Institutions	13:15 - 13:15
<i>Poster Presenter:</i> Miri Assayag, IL	
Outcomes of Subsequent Therapies after Axi-cel or SOC in ZUMA-7	13:15 - 13:15
<i>Poster Presenter:</i> Marie José Kersten, NL	
Coagulopathy and Endothelial Activation in CAR-T Therapy	13:15 - 13:15
<i>Poster Presenter:</i> Eugenio Galli, IT	
Cost-effectiveness of Brexucabtagene for Refractory/Relapsed Acute Lymphoblastic Leukemia	13:15 - 13:15
Combination of CAR30 and Chimeric Costimulatory Receptor Enhances Antitumor Activity	13:15 - 13:15
<i>Poster Presenter:</i> Eva Escudero López, ES	
CAR T-cells vs Allogeneic Transplantation in Relapsed Large B-cell Lymphoma	13:15 - 13:15
<i>Poster Presenter:</i> Peter Dreger, DE	
CD3e Gene Editing to Redirect Regulatory T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Weijie Du, DE	
Adoptive Cell Therapy of Acute Leukemia across MHC-barriers	13:15 - 13:15
<i>Poster Presenter:</i> Michela Consonni, IT	
Durable Responses Assessment after Brexu-cel for R/R MCL in ZUMA-2	13:15 - 13:15
<i>Poster Presenter:</i> Marie José Kersten, NL	
Mouse Model of CAR-related ICANS Development Following hCD19 CAR-T Treatment	13:15 - 13:15
<i>Poster Presenter:</i> Rita El Houry, IT	
T2EVOLVE Consortium for the Optimization of Engineered T-cells Toxicity Models	13:15 - 13:15
<i>Poster Presenter:</i> Monica Casucci, IT	
LMP2A-targeting CAR-T Cells and TRUCKs to Treat EBV-associated Malignancies	13:15 - 13:15
<i>Poster Presenter:</i> Britta Eiz-Vesper, DE	
Microbial Metabolite-guided Engineering of CAR T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Maik Luu, DE	
Engineering Molecular Switches for Functional Control of CAR T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Michael W. Traxlmayr, AT	
CAR T-cells Targeting FLT3-positive AML	13:15 - 13:15
<i>Poster Presenter:</i> Maya Pedersen, DK	

Co-stimulatory Domain CD28/CD40 of CAR	13:15 - 13:15
<i>Poster Presenter:</i> Wannakorn Khopanalert, TH	
Redirection of T Cells and NK Cells by CD3-zeta Editing	13:15 - 13:15
<i>Poster Presenter:</i> Jonas Kath, DE	
Optimized Allogeneic CAR-T Therapies for AML with SB Transposons	13:15 - 13:15
<i>Poster Presenter:</i> Juan R. Rodriguez-Madoz, ES	
CXCR4-overexpressing CD33.CAR-Clk Eliminates BM AML Cells	13:15 - 13:15
<i>Poster Presenter:</i> Marta Biondi, IT	
A Gene Signature in Leukapheresis Predicts Anti-CD19 CAR-T Cell Outcome	13:15 - 13:15
<i>Poster Presenter:</i> Cristiana Carniti, IT	
CD84-targeted CART-cell Therapy for the Treatment of Acute Myeloid Leukemia	13:15 - 13:15
<i>Poster Presenter:</i> Lorena Pérez-Amill, ES	
First Real World Data from the Austrian CAR-T Network	13:15 - 13:15
<i>Poster Presenter:</i> Jakob Daniel Rudzki, AT	
Different Editing Outcomes of CRISPR PE in HEK293T and T-cells	13:15 - 13:15
<i>Poster Presenter:</i> Karl Petri, US	
Donor-derived CAR-T Cells Co-infusion with T-depleted HSCT	13:15 - 13:15
<i>Poster Presenter:</i> Arina Rakhteenko, RU	
Prophylactic Corticosteroids with Axi-cel: ZUMA-1 Cohort 6 2-year Follow-up	13:15 - 13:15
<i>Poster Presenter:</i> Tom van Meerten, NL	
Disease Stage Affects CAR-T Cell Function	13:15 - 13:15
<i>Poster Presenter:</i> Juan R. Rodriguez-Madoz, ES	
Clinical Grade ROR1 CAR T-cells against Haematologic and Solid Malignancies	13:15 - 13:15
<i>Poster Presenter:</i> Sabrina Prommersberger, DE	
Generation and Functional Analysis of HBV-specific FabCARs	13:15 - 13:15
<i>Poster Presenter:</i> Zhe Xie, DE	
Pre-clinical Validation of Co-transduced CD19/BCMA Dual-CAR-T Cells for NHL	13:15 - 13:15
<i>Poster Presenter:</i> Mireia Bachiller, ES	
Monitoring CAR-T Cells: Looking for Early Biomarkers as Predictive Factors	13:15 - 13:15
<i>Poster Presenter:</i> Beatriz Guijarro-Albaladejo, ES	
Myeloid Cells and CAR T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Camille Bigenwald, FR	

Systematic Literature Review of Real-world Evidence on Axicabtagene-ciloleucel and Tisagenlecleucel	13:15 - 13:15
<i>Poster Presenter:</i> Fang Sun, US	
Superiority of CD4⁺ CARTs	13:15 - 13:15
<i>Poster Presenter:</i> Qian Chen, DE	
Dual Modified Primary CD33-directed CAR-NK Cells for Treatment of AML	13:15 - 13:15
<i>Poster Presenter:</i> Nawid Albinger, DE	
Early Management CRS and Outcome of DLBCL Treated with CAR-T	13:15 - 13:15
<i>Poster Presenter:</i> Ana Africa Martin Lopez, ES	
Initial Clinical Results of Point-of-Care Manufactured GLPG5101 in RR NHL	13:15 - 13:15
<i>Poster Presenter:</i> Kirsten Saevels, BE	
Cytotoxicity of CAR-T-cells from DLBCL Patients in High Resolution Microscopy	13:15 - 13:15
<i>Poster Presenter:</i> Eva C Schwarz, DE	
Update on HD-CAR-1 Trial: 3rd-generation CD19-directed CARTs for Relapsed/Refractory CLL	13:15 - 13:15
<i>Poster Presenter:</i> Patrick Derigs, DE	
TME Targeting CAR-T Cells for Solid Tumors	13:15 - 13:15
<i>Poster Presenter:</i> Juan R. Rodriguez-Madoz, ES	
Rituximab + CFM/FLU Lymphodepletion Followed by Second CART19 in B-ALL	13:15 - 13:15
<i>Poster Presenter:</i> Valentin Ortiz-Maldonado, ES	
3G.CARTs for ALL	13:15 - 13:15
<i>Poster Presenter:</i> Michael Schmitt, DE	
The Endothelium Involvement during CRS: First Reported Case of CAR-VOD	13:15 - 13:15
<i>Poster Presenter:</i> Manuela Spadea, IT	
Clonal Hematopoiesis and Manufacturing of CAR T-lymphocytes	13:15 - 13:15
CECs in CAR-T cells Associated CRS and ICANS	13:15 - 13:15
<i>Poster Presenter:</i> Irene Defrancesco, IT	
Cytopenias after CAR-T in Real World: Utility of CAR-HEMATOTOX	13:15 - 13:15
Novel Modular SIRPalpha Based Chimeric Antigen Receptors	13:15 - 13:15
<i>Poster Presenter:</i> Jan Koski, FI	
Initial Clinical Results of Point-of-Care Manufactured GLPG5201 in R/R CLL/SLL	13:15 - 13:15
<i>Poster Presenter:</i> Julio Delgado, ES	

Metabolic Reprogramming of CAR T Cell Phenotype	13:15 - 13:15
<i>Poster Presenter: Mathias Wenes, CH</i>	
Proteasomal Inhibition Sensitizes AML Cells to CAR NK-cell Mediated Killing	13:15 - 13:15
<i>Poster Presenter: David Sedloev, DE</i>	
CAR-Treg for Systemic Lupus Erythematosus	13:15 - 13:15
<i>Poster Presenter: Matteo Doglio, IT</i>	
Chasing the Epigenetic Landscape to Prevent CD19 Antigen Escape	13:15 - 13:15
<i>Poster Presenter: Narendra Varma Gottumukkala, CZ</i>	
Outcomes of T2Evolve Survey on CAR T Cell Analytical Methods	13:15 - 13:15
<i>Poster Presenter: Pacôme Lecot, FR</i>	
Inflammatory Reactions after CAR T-cell Therapy	13:15 - 13:15
<i>Poster Presenter: Janneke W de Boer, NL</i>	
Viral Reactivation after CAR-T Cell Therapy	13:15 - 13:15
<i>Poster Presenter: Elisabetta Xue, IT</i>	
Prognostic Impact of MTV in DLBCL Treated with CAR-T	13:15 - 13:15
<i>Poster Presenter: Ana Africa Martin Lopez, ES</i>	
Impact of SARS-CoV-2 Vaccination and Prophylaxis on Car-T Patients Journey	13:15 - 13:15
<i>Poster Presenter: Eugenio Galli, IT</i>	
A Newly Reported ICANS-associated MRI Alteration after CAR-T Cell Therapy	13:15 - 13:15
<i>Poster Presenter: Flavio Pistolese, IT</i>	
Neurotoxicity of CD19-CAR-T-Cells: A Case Report	13:15 - 13:15
<i>Poster Presenter: Conrad Weidt, DE</i>	
TP53 Mutations: Impact in Childhood Outcomes after CD19-CAR T-cell Therapy	13:15 - 13:15
<i>Poster Presenter: Anna Alonso-Saladrigues, ES</i>	
CRS after CAR-T Cell Therapy for MCL: A Case Report	13:15 - 13:15
<i>Poster Presenter: Elenii Gavriilaki, GR</i>	
Effect of Glycine-Serine Linker on CD37CAR-T Efficacy	13:15 - 13:15
<i>Poster Presenter: Wannakorn Khopanlert, TH</i>	
Immune Microenvironment of Patients Undergoing CAR T Cell Therapy	13:15 - 13:15
<i>Poster Presenter: Ulrike Weirauch, DE</i>	
Evaluation of New Immunotherapeutic Targets for Multiple Myeloma	13:15 - 13:15
<i>Poster Presenter: Mégane Jassin, BE</i>	

Real World Experience CAR T-cell Early Failure Predictors	13:15 - 13:15
<i>Poster Presenter:</i> Sita Bhella, CA	
Short-linker CD137-based anti-BCMA CAR	13:15 - 13:15
<i>Poster Presenter:</i> Sophia Stock, DE	
ISIKOK-19 CAR T Cell in ALL with Extramedullary Disease	13:15 - 13:15
<i>Poster Presenter:</i> Koray Yalcin, TR	
pTag Adapter CAR™ T Cells in Preclinical Models	13:15 - 13:15
<i>Poster Presenter:</i> Ulrika Bader, DE	
BrainTRUCK: From NKG2D CAR-T to TRUCK in Pediatric CNS Tumors	13:15 - 13:15
<i>Poster Presenter:</i> Laura Clares-Villa, ES	
Flow Cytometry Detection of CAR-T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Silvia Zaninelli, IT	
CAR T-cells and Cytopenia	13:15 - 13:15
<i>Poster Presenter:</i> Ahmadreza Arbab, FR	
Screening of Novel CARs	13:15 - 13:15
<i>Poster Presenter:</i> Farhana Jahan, FI	
On the Path towards Clinical Manufacturing of CAR ??-T Cells	13:15 - 13:15
<i>Poster Presenter:</i> Lorraine Pinot, DE	
ASCT before Lymphocyte-apheresis Results in a More “Exhausted” T-cells Repertoire	13:15 - 13:15
<i>Poster Presenter:</i> Mirko Farina, IT	
Donor-derived Myeloid Antigen-directed CAR-T Cells in R/R AML in Children	13:15 - 13:15
<i>Poster Presenter:</i> Olga Molostova, RU	
Thrombopoietin Receptor Agonist after Anti-CD19 CAR-T Cells: A Case Report	13:15 - 13:15
<i>Poster Presenter:</i> Stefania Bramanti, IT	
Changes in Phenotype of T Cells / CD19 CAR-T Cells in the Course of Patient Treatment	13:15 - 13:15
<i>Poster Presenter:</i> Jonas Wißkirchen, DE	
Optimizing LD within T2EVOLVE	13:15 - 13:15
HCT after CAR-T in ALL	13:15 - 13:15
<i>Poster Presenter:</i> Nico Gagelmann, DE	
Pembrolizumab after CAR-T	13:15 - 13:15
<i>Poster Presenter:</i> Ana Africa Martin Lopez, ES	
Real Life CAR-T for ALL Adult Patients	13:15 - 13:15
<i>Poster Presenter:</i> Eugenio Galli, IT	
Autologous Stem Cell Boost in Cytopenia after CAR-T Cells	13:15 - 13:15

Radiation Therapy as Bridge to CAR-T	13:15 - 13:15
<i>Poster Presenter:</i> Marcello Riva, IT	
Impacts of CAR-T Cell Therapies in a French Academic Hospital	13:15 - 13:15
<i>Poster Presenter:</i> Lucas Fleta, FR	
Academic Development of a Lentiviral Vector vs CD19	13:15 - 13:15
<i>Poster Presenter:</i> Alberto Olaya-Vargas, MX	
Laboratory BCP-ALL Patient Follow-up after CAR-T Cell Treatment	13:15 - 13:15
<i>Poster Presenter:</i> Martijn Verbeek, NL	
Improving the CAR T-cell Treatment Journey and Access across Europe	13:15 - 13:15
<i>Poster Presenter:</i> Elise Pennings, NL	
Approaching Regulatory Challenges for Engineered T Cell Therapies in Europe	13:15 - 13:15
<i>Poster Presenter:</i> Paul Franz, DE	
ZUMA-25: Brexu-cel in Patients with R/R Rare B-cell Malignancies	13:15 - 13:15
<i>Poster Presenter:</i> M. Lia Palomba, US	
2 Years of Experience and Implications of Nursing Improvement	13:15 - 13:15
Educational Requirements in the United Kingdom's CAR-T Ecosystem	13:15 - 13:15
<i>Poster Presenter:</i> Maria Garcia Gomez, GB	
Trust and Acceptance AI Applications in Medicine	13:15 - 13:15
<i>Poster Presenter:</i> Anam Ahmed, NL	
A Case of Multiply Relapsed B-ALL	13:15 - 13:15
<i>Poster Presenter:</i> Erma Gardner, CA	
Starting Material and Successful Manufacturing of Commercial Carts	13:15 - 13:15
<i>Poster Presenter:</i> Jesus Fernandez-Sojo, ES	
CAR-T Cell Dynamics in Treated Patients: A Real-life Cohort Study	13:15 - 13:15
<i>Poster Presenter:</i> Maddalena Noviello, IT	
Early Lymphopheresis Collection Improves CART Fitness in r/r DLBCL Patients	13:15 - 13:15
<i>Poster Presenter:</i> Tatyana Dubnikov Sharon, IL	
Impact of LDH at Apheresis and Lymphodepletion on Outcome after CD19 CAR T Cell Therapy	13:15 - 13:15
<i>Poster Presenter:</i> Isabelle Ries, DE	
PPI Exploring CAR T-cell Therapy Patients' Experiences and Priorities	13:15 - 13:15
<i>Poster Presenter:</i> Nikoletta Mama, GB	

	Sinus Bradycardia: A Symptom of ICANS after CAR T-cell Therapy	13:15 - 13:15
	<i>Poster Presenter:</i> Sofie-Katrin Kadel, DE	
	The Role of the CAR-T Advanced Nurse Practitioner in CAR-T Cell Therapy Promoting and Adhering to the Immunization Schedule	13:15 - 13:15
	<i>Poster Presenter:</i> Mercedes Montoro-Lorite, ES	
	Different Toxicity in CART Cells: Real-world Experience	13:15 - 13:15
	<i>Poster Presenter:</i> Elenii Gavriilaki, GR	
	CAR-T for Central Nervous System Lymphoma	13:15 - 13:15
	<i>Poster Presenter:</i> Marcello Riva, IT	
	Presentation of a Complex Case Managed by the Synergy of Several Professionals	13:15 - 13:15
	<i>Poster Presenter:</i> Alfonso Parisi, IT	
	CAR-T Therapy of Diffuse Large B Cell Lymphoma	13:15 - 13:15
	<i>Poster Presenter:</i> Milica Miljkovic, SI	
	Identification and Isolation of Single Immune Cells Based on Function with Xdrop®	13:15 - 13:25
	<i>Poster Presenter:</i> Peter Mouritzen, DK	
<i>Keynote</i>		
14:00 - 18:00		On-Demand
	KN04 - Keynote Lecture Novel CAR-T Therapy of Relapse or Refractory Hematological Malignancies	
KN04-on demand	Novel CAR-T Therapy of Relapse or Refractory Hematological Malignancies	14:00 - 14:30
	<i>Speaker:</i> He Huang, CN	
<i>Physicians Session</i>		
15:00 - 16:30		Plenary
	PS02 - Clinical Indications II - Acute & Chronic Leukaemias	
	<i>Chair:</i> Annalisa Ruggeri, IT	
	<i>Chair:</i> John Gribben, GB	
	<i>Chair:</i> Stephan Mielke, SE	
PS02-1	Acute Lymphoblastic Leukemia (ALL)	15:00 - 15:20
	<i>Speaker:</i> André Baruchel, FR	
PS02-2	Novel targets and technologies for CAR-T cells in AML	15:20 - 15:45
	<i>Speaker:</i> Michael Hudecek, DE	
PS02-3	Chronic Lymphocytic Leukemia (CLL)	15:45 - 16:10
	<i>Speaker:</i> John Gribben, GB	
PS02-4	T-cell Acute Lymphoblastic leukemia (T-ALL)/Treating T-Cell Non-Hodgkin Lymphoma (T-NHL)	16:10 - 16:30
	<i>Speaker:</i> Maksim Mamonkin, US	

Break

16:30 - 17:00

Foyer

CB1 - Coffee Break in the Foyer

Industry Theatre

16:35 - 16:55

IT

IT1 - Industry Theatre: Novel manufacturing technologies that enable advanced T cell generation by Bristol Myers Squibb

Expert: Mateusz Poltorak, DE

Best Abstracts

17:00 - 17:30

Plenary

BA1 - Best Abstract Session & Awards

Chair: Anna Sureda, ES

Chair: Michael Hudecek, DE

- | | | |
|--------|--|---------------|
| BA01-1 | CAR T Cells Targeting Tumor and Stroma in PDAC
<i>Oral Presenter:</i> Marc Wehrli, US | 17:00 - 17:10 |
| BA01-2 | Single-cell Dissection of Anti-BCMA CARs in MM
<i>Oral Presenter:</i> Vladan Vucinic, DE | 17:10 - 17:20 |
| BA01-3 | IF-BETTER-gated CAR T Cells to Safely Target AML with Minimal Escape
<i>Oral Presenter:</i> Sascha Haubner, US | 17:20 - 17:30 |

Keynote

17:30 - 18:00

Plenary

KN1 - Keynote Lecture

Chair: Alejandro Madrigal, GB

Chair: Alina Daniela Tanase, RO

- | | | |
|------|--|---------------|
| KN01 | Keynote Lecture: Bringing CAR T to the next generation for efficacy and safety
<i>Speaker:</i> Maria Themeli, NL | 17:30 - 18:00 |
|------|--|---------------|

Satellite Symposium

18:15 - 19:00

Plenary

SS1 - Satellite Symposium | Optimizing CAR T cell therapy experience in the real world: an outside-the-box discussion | by Bristol Myers Squibb

Chair: Salomon Manier, FR

- | | | |
|--------|--|---------------|
| SS01-1 | Panel discussion > Join our esteemed international panel of experts in a conversation that ventures outside the box, discussing the latest in multiple myeloma CAR T-cell real-world evidence. In this live interactive discussion integrating myeloma and lymphoma expertise, we will explore how real-world evidence can inform optimal patient identification, efficacy, toxicity management, and future perspectives of patient care.
<i>Speaker:</i> Marion Subklewe, DE
<i>Speaker:</i> Doris Hansen, US | 18:15 - 19:00 |
|--------|--|---------------|

Physicians Session

19:00 - 20:00

Foyer

NW1 - Welcome Reception and Poster Exhibition

Meet-the-Experts

19:00 - 20:30

Foyer

MTE03 - Meet-the-Experts Session 3

Expert: Claire Roddie, GB

Meet Prof Roddie

19:00 - 19:30

Meet-the-Experts

19:00 - 20:30

Foyer

Welcome Reception | Poster exhibition | Meet the Experts

Meet-the-Experts

19:00 - 20:30

Foyer

MTE01 - Meet-the-Experts Session 1

Expert: Marco Ruella, US

Meet Prof Ruella

19:00 - 19:30

Meet-the-Experts

19:00 - 20:30

Foyer

MTE02 - Meet-the-experts Session 2

Expert: Carl June, US

Meet Dr June

19:00 - 19:30

Friday, 10. February 2023

Keynote

09:00 - 09:50

Plenary

KN2 - Keynote Lecture

Chair: Michelle Kenyon, GB

Chair: Michael Hudecek, DE

Chair: Anna Sureda, ES

Chair: Carl June, US

KN02 **Journey to CAR-T Cell Therapy & Beyond, Emily Whitehead's Story** 09:00 - 09:45
Speaker: Tom Whitehead, US

Keynote

09:00 - 18:00

On-Demand

KN04 - Keynote Lecture | Novel CAR-T Therapy of Relapse or Refractory Hematological Malignancies

KN04-on demand **Novel CAR-T Therapy of Relapse or Refractory Hematological Malignancies** 09:00 - 09:30
Speaker: He Huang, CN

Poster Session

09:00 - 18:00

Poster Area

Poster Posters are at the exhibition area during the 3 days of the meeting and available on the virtual event platform. There is not any scheduled presentation.

Physicians Session

10:00 - 11:00

Plenary

PS03 - Clinical Indications III - Multiple Myeloma

Chair: Ibrahim Yakoub-Agha, FR

Chair: Paula Rodriguez Otero, ES

PS03-1 **Overview** 10:00 - 10:20
Speaker: Hermann Einsele, DE

PS03-2 **CAR T myeloma ; biomarkers, PK, risk factors** 10:20 - 10:40
Speaker: Philippe Moreau, FR

PS03-3 **AR1cel in MM/Amyloidosis** 10:40 - 11:00
Speaker: Carlos Fernandez de Larrea, ES

Nurses Session

10:00 - 11:00

BR1

NG01 - Opening and Session 1

Chair: Erik Aerts, CH

Chair: Michelle Kenyon, GB

NG0 **Opening** 10:00 - 10:05

NG01-1 **Haematology Nurses and Healthcare Professionals (Hnhcp) – CAR T-cell therapy learning program: a resource for healthcare** 10:05 - 10:15

	professionals	
	<i>Speaker:</i> Erik Aerts, CH	
NG01-1	IEC Forum	10:15 - 10:20
	<i>Speaker:</i> Ruth Clout, GB	
NG01-4	The nurse and the patient pathway	10:20 - 10:40
	<i>Speaker:</i> Rose Ellard, GB	
NG01-3	CAR T Cell therapy: past , present, future	10:40 - 11:00
	<i>Speaker:</i> Elaine Vickers, GB	
<i>Break</i>		
11:00 - 11:30		Foyer
CB2 - Coffee Break		
<i>Physicians Session</i>		
11:30 - 13:00		Plenary
PS04 - Clinical Indications IV - Solid Tumors & Keynote lecture		
<i>Chair:</i> Fabio Ciceri, IT		
<i>Chair:</i> Annette Künkele, DE		
KN03-PS04-1	Keynote lecture on PSMA/Other solid tumors	11:30 - 12:00
	<i>Speaker:</i> Carl June, US	
PS04-2	Solid tumor pipeline	12:00 - 12:20
	<i>Speaker:</i> Sonia Guedan, ES	
PS04-3	Advancing CAR T Cell Therapy for Glioblastoma	12:20 - 12:40
	<i>Speaker:</i> Christine Brown, US	
PS04-4	Paediatrics CAR-Ts	12:40 - 13:00
	<i>Speaker:</i> Concetta Quintarelli, IT	
<i>Nurses Session</i>		
11:30 - 12:15		BR1
NG02 - Session 2		
<i>Chair:</i> Ruth Clout, GB		
<i>Chair:</i> Rose Ellard, GB		
NG02-1	Disease update lymphoma, leukaemia and Myeloma	11:30 - 11:55
	<i>Speaker:</i> Ibrahim Yakoub-Agha, FR	
NG02-2	Horizon scanning: paediatrics	11:55 - 12:15
	<i>Speaker:</i> Marjola Gjergji, IT	
<i>Nurses Session</i>		
12:15 - 13:00		BR1
NG03 - Session 3		
<i>Chair:</i> Ruth Clout, GB		
<i>Chair:</i> Rose Ellard, GB		
NG03-1	From prehab to rehab: nutritional support in patients treated with CAR-T therapy	12:15 - 12:30

	<i>Speaker:</i> Amanda Casirati, IT	
NG03-2	Adapted Physical Activity <i>Speaker:</i> Nicolas Brelot, FR	12:30 - 12:45
NG03-3	Prehab/ rehab psychology <i>Speaker:</i> Vera Hinderling-Baertschi, CH	12:45 - 13:00

Break

13:00 - 14:30

Foyer

LB1 - Lunch Break

Industry Theatre

13:05 - 13:25

IT

IT3 - Industry Theatre | Kite: Leader in cell therapy

IT3-1	Leader in cell therapy <i>Speaker:</i> Dick Sundh, DE	13:05 - 13:25
-------	---	---------------

Satellite Symposium

13:30 - 14:15

Plenary

SS2 - Bringing CAR T into second line in DLBCL | Satellite symposium sponsored by Kite

Chair: Tom van Meerten, NL

SS2-1	Introduction to the symposium	13:30 - 13:33
SS2-2	Defining the unmet need in second-line DLBCL <i>Speaker:</i> Wendy Osborne, GB	13:33 - 13:48
SS2-2	How has CAR T changed the second-line DLBCL treatment landscape? <i>Speaker:</i> Tom van Meerten, NL	13:48 - 14:08
SS2-3	Q&A	14:08 - 14:13
SS2-4	Close	14:13 - 14:15

Physicians Session

14:30 - 15:00

Plenary

PS05 - Patient perspective on CAR-T Round table

Chair: Natacha Bolaños, ES

Chair: Solène Clavreul, FR

PS05-1	Roundtable discussion <i>Panellist:</i> Martine Elias, CA <i>Panellist:</i> Lorna Warwick, CA	14:30 - 15:00
--------	--	---------------

Nurses Session

14:30 - 15:15

BR1

NG04 - Session 4

Chair: Ruth Clout, GB

Chair: Rose Ellard, GB

NG04-1	Early and late infections in patients undergoing CAR T-cell Therapy <i>Speaker:</i> Andriyana Bankova, CH	14:30 - 14:45
NG04-2	Experiences of CAR T Cell Therapy: What Nurses report <i>Speaker:</i> Martina Spalt, AT	14:45 - 15:00
NG04-3	Advance care planning <i>Speaker:</i> Jennifer Vidrine, GB	15:00 - 15:15

Keynote

15:00 - 15:30

Plenary

KN5 - Keynote Lecture

Chair: Dirk Busch, DE

Chair: Chiara Bonini, IT

KN01	Mechanisms driving CAR T cells <i>Speaker:</i> Marcela Maus, US	15:00 - 15:30
------	---	---------------

Nurses Session

15:15 - 16:30

BR1

NG05 - Session 5

Chair: Ruth Clout, GB

Chair: Rose Ellard, GB

NG05-1	Ethical considerations <i>Speaker:</i> Anna Castleton, GB	15:15 - 15:35
NG05-2	CAR T-Cell Therapies: A Patient's Perspective <i>Speaker:</i> Jonathan Clark, NL	15:35 - 15:55
NG05-3	CAR T-cell Therapy: Patients- and Family Caregivers' Needs Post-treatment <i>Oral Presenter:</i> Britt Snoek, NL	15:55 - 16:05
NG05-4	Nutritional Status during CAR-T Therapy <i>Oral Presenter:</i> Nicola Scott, GB	16:05 - 16:15
NG05-5	Panel Discussion	16:15 - 16:30

Physicians Session

15:30 - 16:30

Plenary

PS06 - CAR-T Innovation Pipeline

Chair: Maria Themeli, NL

Chair: Ciprian Tomuleasa, RO

PS06-1	Pre-selection of naive T cells and tumor deglycosylation to improve CAR-T cell therapy <i>Speaker:</i> Monica Casucci, IT	15:30 - 15:50
PS06-2	Pooled CRISPR Knockin Screens: Reprogramming Therapeutic T Cells <i>Speaker:</i> Franziska Blaeschke, US	15:50 - 16:10

Saturday, 11. February 2023

Physicians Session
08:30 - 09:40

Plenary

PS07 - New Academic Initiatives & CAR-T Therapy Networks

Chair: Chiara Bonini, IT

Chair: Natacha Bolaños, ES

PS07-1	GoCART Initiative <i>Speaker:</i> Jürgen Kuball, NL	08:30 - 08:44
PS07-2	The EBMT Registry: monitoring CAR-T Cells and IECs activities in Europe <i>Speaker:</i> Christian Chabannon, FR	08:44 - 08:58
PS07-3	IMI EU T2EVOLVE <i>Speaker:</i> Carmen Sanges, DE	08:58 - 09:12
PS07-4	Advanced Therapies Network Spain <i>Speaker:</i> Jose M. Moraleda, ES	09:12 - 09:26
PS07-5	CAR-T Switzerland <i>Speaker:</i> Caroline Arber, CH	09:26 - 09:40

Physicians Session
08:30 - 09:40

BR1

PS08 - Clinical Management of CAR-T Patients

Chair: Arnon Nagler, IL

Chair: Valentin Ortiz-Maldonado, ES

PS08-1	Patient perspective: CAR-T Journey <i>Speaker:</i> Kenneth Casler, FR	08:30 - 08:40
PS08-2	Car-HLH: A devastating complication following Chimeric Antigen Receptor T-cell (CAR-T cell) therapy <i>Oral Presenter:</i> Muhammad Gohar Maqbool, GB	08:40 - 08:48
PS08-2	Case presentation discussion: adult lymphoma <i>Panellist:</i> Catherine Thieblemont, FR <i>Panellist:</i> Peter Dreger, DE	08:48 - 09:00
PS08-3	Successful Treatment of Romiplostim for Persistent Thrombocytopenia Following CAR-T Cell Therapy in Phi+ B-ALL: A Case Report <i>Oral Presenter:</i> Julien Dereme, CH	09:00 - 09:08
PS08-3	Case presentation discussion: adult ALL <i>Panellist:</i> Mohamad Mohty, FR <i>Panellist:</i> Claire Roddie, GB	09:08 - 09:20
PS8-4	Myositis in a patient with relapsed/refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy <i>Oral Presenter:</i> Sofía Huerga Domínguez, ES	09:20 - 09:28

PS08-4 **Case presentation discussion: Multiple Myeloma** 09:28 - 09:40
Panellist: Paula Rodriguez Otero, ES
Panellist: Michel Delforge, BE

Poster Session
 08:30 - 14:30

Poster Area

Poster Posters are at the exhibition area during the 3 days of the meeting and available on the virtual event platform. There is not any scheduled presentation.

Keynote

09:00 - 14:00

On-Demand

KN04 - Keynote Lecture | Novel CAR-T cellular therapy for hematological malignancies

KN04-on demand **Novel CAR-T Therapy of Relapse or Refractory Hematological Malignancies** 09:00 - 09:30
Speaker: He Huang, CN

Satellite Symposium

09:45 - 10:30

Plenary

SS4 - CAR-T Cell Therapy expands the horizon for patients with Multiple Myeloma | Satellite Symposium by Janssen

Chair: Mohamad Mohty, FR

SS4-1 **Welcome and introduction** 09:45 - 09:50
Speaker: Mohamad Mohty, FR

SS4-2 **Where are we now with CAR-T cell therapy in MM?** 09:50 - 10:05
Speaker: Paula Rodriguez Otero, ES

SS4-3 **Where are we going with CAR-T cell therapy in MM?** 10:05 - 10:20
Speaker: Pieter Sonneveld, NL

Panel discussion with Q&A | Closing remarks 10:20 - 10:30

Physicians Session

10:40 - 11:50

Plenary

PS09 - Advanced concepts for CAR-T manufacturing

Chair: Halvard Bönig, DE

Chair: Concetta Quintarelli, IT

PS09-1 **Overview** 10:40 - 10:55
Speaker: Ulrike Köhl, DE

PS09-2 **Point-of-care CAR-T manufacture** 10:55 - 11:10
Speaker: Alvaro Urbano Ispizua, ES

PS09-3 **Rapid CAR-T manufacture** 11:10 - 11:25
Speaker: Nina Worel, AT

PS09-4 **Point-of-care ATMP manufacture** 11:25 - 11:40
Speaker: Harry Dolstra, NL

PS09-5 **Panel discussion** 11:40 - 11:50

Physicians Session

10:40 - 11:50

BR1

PS10 - Toxicity Management

Chair: Zinaida Peric, HR

Chair: Patrick Hayden, IE

PS10-1	European Guidelines <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	10:40 - 10:55
PS10-2	Hematologic Toxicity <i>Speaker:</i> Marion Subklewe, DE	10:55 - 11:10
PS10-3	COVID <i>Speaker:</i> Marie José Kersten, NL	11:10 - 11:25
PS10-4	Panel discussion	11:25 - 11:50

Physicians Session

12:00 - 13:10

Plenary

PS11 - International Session - Access to CAR-T on a Global Scale

Chair: Christian Chabannon, FR

Chair: Ulrike Köhl, DE

PS11-1	South America <i>Speaker:</i> Vanderson Rocha, BR	12:00 - 12:12
PS11-2	Central and Eastern Europe <i>Speaker:</i> Roman Hajek, CZ	12:12 - 12:24
PS11-3	South Africa <i>Speaker:</i> Candice Hendricks, ZA	12:24 - 12:36
PS11-4	Canada <i>Speaker:</i> Kevin Hay, CA	12:36 - 12:48
PS11-5	India <i>Speaker:</i> Gaurav Narula, IN	12:48 - 13:00
PS11-6	Roundtable discussion <i>Speaker:</i> Martine Elias, CA	13:00 - 13:10

Physicians Session

12:00 - 13:10

BR1

PS12 - Failure of CAR-T - What is next?

Chair: Raffaella Greco, IT

Chair: Natacha Bolaños, ES

Chair: Koray Yalcin, TR

PS12-1	Patient perspective: Fear of relapse <i>Speaker:</i> Lorna Warwick, CA	12:00 - 12:10
PS12-2	Case Presentation (Lymphoma): AML after CAR-T Therapy in Relapsed High-grade Non-Hodgkin B Lymphoma <i>Oral Presenter:</i> Juan Francisco López Rodríguez, ES	12:10 - 12:18

PS12-2	Case presentation discussion: adult lymphoma <i>Panellist:</i> Paolo Corradini, IT <i>Panellist:</i> Raffaella Greco, IT	12:18 - 12:30
PS12-3	Case Presentation (ALL):Inotuzumab Ozogamicin Bridges to Allo-HSCT Post-CAR T-cell Relapse in BCP-ALL <i>Oral Presenter:</i> Margo Aertgeerts, BE	12:30 - 12:38
PS12-3	Case presentation discussion: Paediatric ALL <i>Panellist:</i> Sara Ghorashian, GB <i>Panellist:</i> Annette Künkele, DE	12:38 - 12:50
PS12-4	Case Presentation (MM): Sequential Therapy with Teclistamab after Failure of BCMA-directed CAR-T Therapy <i>Oral Presenter:</i> Lukas Scheller, DE	12:50 - 12:58
PS12-4	Case presentation discussion: Multiple Myeloma <i>Panellist:</i> Maria Victoria Mateos, ES <i>Panellist:</i> Sophia Danhof, DE	12:58 - 13:10
<i>Break</i>		
13:10 - 13:30		Foyer
CB4 - Lunch boxes delivery		
<i>Best Abstracts</i>		
13:30 - 14:00		Plenary
BA3 - Best Abstract Session		
<i>Chair:</i> Anna Sureda, ES		
<i>Chair:</i> Michael Hudecek, DE		
BA03-1	Third-generation TLR2 Co-stimulated CAR T-cells for B-cell Malignancies <i>Oral Presenter:</i> Yasmin Nouri, NZ	13:30 - 13:40
BA03-2	Impact of Gut Microbiota in the Efficacy of CART-cell Therapy <i>Oral Presenter:</i> Mireia Uribe-Herranz, ES	13:40 - 13:50
BA03-3	Dual CD30/PDL1 CAR-T Cell Strategy in Classic Hodgkin's Lymphoma <i>Oral Presenter:</i> Vincenzo Maria Perriello, IT	13:50 - 14:00
<i>Keynote</i>		
14:00 - 14:30		Plenary
KN6 - Keynote Lecture		
<i>Chair:</i> Anna Sureda, ES		
<i>Chair:</i> Michael Hudecek, DE		
KN06	Antigen sensitivity, persistence and gated control of CAR T cells <i>Speaker:</i> Michel Sadelain, US	14:00 - 14:30

Physicians Session

14:30 - 14:45

Plenary

CLS - Closing remarks

Chair: Anna Sureda, ES

Chair: Michael Hudecek, DE